A Study Comparing the Pharmacokinetics and Tolerance of D-Gam® to Rhophylac® in Rh-D-negative Healthy Volunteers.
NCT ID: NCT02246842
Last Updated: 2018-03-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
INTERVENTIONAL
2004-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Efficacy of Postpartum Immunization of Rh and Coombs Negative Women With Sensitization Risk.
NCT01666249
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
NCT02541942
An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients
NCT02231944
Pharmacokinetics and Safety of Roledumab in RhD-negative Pregnant Women Carrying an RhD-positive Foetus
NCT02287896
A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years
NCT02263469
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
D-Gam®
D-Gam® (human anti-D immunoglobulin)
D-Gam® (human anti-D immunoglobulin)
Rhophylac®
Human Anti-D Immunoglobulin
Rhophylac® (human anti-D immunoglobulin)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
D-Gam® (human anti-D immunoglobulin)
Rhophylac® (human anti-D immunoglobulin)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ages of 18 and 55 years
* Bodyweight of 50-85kg.
Exclusion Criteria
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bio Products Laboratory
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr A Sutton, MB BS, FFARCSI
Role: PRINCIPAL_INVESTIGATOR
Guildford Clinical Pharmacology Unit
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guildford Clinical Pharmacology Unit
Unit 34, Surrey Technology Centre, Surrey Research Park, Occam Road, Guildford, Surrey, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Sponsor's Homepage
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
POLYAD04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.